STAT+: Immunovant shares surge on arthritis trial data

Immunovant shares surge following positive arthritis trial data. UCSF researchers have submitted an FDA application for a prenatal gene therapy targeting a severe neurodegenerative disorder affecting young children. FDA leadership instability is causing investor concern and impacting rare disease drug development.